Loading
Everything OnCo dates to 2002: 98 entries, 30 landmarks, 18 papers, 12 approvals and 12 papers listed on people's pages. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
98 dated entries in OnCo fall in 2002: 30 landmarks, 18 papers, 12 approvals, 12 papers listed on people's pages, 8 companies founded, 7 journals founded, 6 regulatory events, 3 trials reported, 1 law or regulation and 1 technology.
Of those, 6 to the day and 92 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Small cell lung cancer and non-small cell lung cancer
Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
APL
Anaemia due to concomitant myelosuppressive chemotherapy in non-myeloid malignancies
HR+ advanced breast cancer after antioestrogen therapy
Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma
KIT+ GIST
Metastatic colorectal cancer with 5-FU/LV
Reduction in duration of neutropenia and febrile neutropenia after cytotoxic chemotherapy (Neulasta); biosimilars from 2018
Decrease in febrile neutropenia in non-myeloid malignancies on myelosuppressive chemotherapy (acute radiation syndrome added 2015)
Initial management of plasma uric acid in paediatric patients with leukaemia, lymphoma or solid tumours at risk of tumour lysis (adults added 2009)
Multiple myeloma and bone metastases from solid tumours, with antineoplastic therapy
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
KIT (CD117) positive unresectable and/or metastatic GIST. KIT+ gastrointestinal stromal tumour
Relapsed or refractory low-grade follicular or transformed B-cell NHL other than rituximab-refractory follicular NHL.
In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV an...
Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Supportive Care: Prevention of cardiomyopathy associated with doxorubicin administration. Confirmed: the accelerated approval of 1995 converted to traditional approval 7.4 years af...
Newly diagnosed adults with Philadelphia chromosome positive CML. Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
United States, statute.
The year reported on trial records, with the headline result the record gives.
Twenty-year same-breast recurrence 8.8 percent after quadrantectomy against 2.3 percent after radical mastectomy, with identical survival (death from any cause 41.7 against 41.2 pe...
No significant difference in disease-free, relapse-free, distant-disease-free or overall survival between radical mastectomy, total mastectomy with irradiation and total mastectomy...
Twenty-year recurrence in the treated breast 14.3 percent with lumpectomy and irradiation against 39.2 percent with lumpectomy alone; no difference in overall survival between any...
The publication year on key paper records.
Llovet JM, Real MI, Montaña X, et al. The Lancet.
Dunn GP, Bruce AT, Ikeda H, et al. Nature immunology.
Schiller JH, Harrington D, Belani CP, et al. New England Journal of Medicine.
Coussens LM, Werb Z. Nature.
Bell SP, Dutta A. Annual review of biochemistry.
Mathijssen RH, Verweij J, de Bruijn P, et al. JNCI: Journal of the National Cancer Institute.
Demetri GD, von Mehren M, Blanke CD, et al. New England Journal of Medicine.
FIGO Oncology Committee. International Journal of Gynecology & Obstetrics.
Jaffray DA, Siewerdsen JH, Wong JW, et al. International Journal of Radiation Oncology, Biology, Physics.
Hensley ML, Maki R, Venkatraman E, et al. Journal of Clinical Oncology.
Neumann HP, Bausch B, McWhinney SR, et al. New England Journal of Medicine.
Birkmeyer JD, Siewers AE, Finlayson EV, et al. New England Journal of Medicine.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. PNAS.
O'Sullivan B, Davis AM, Turcotte R, et al. The Lancet.
Kothari AS, Beechey-Newman N, Hamed H, et al. Cancer.
Rosenwald A, Wright G, Chan WC, et al. New England Journal of Medicine.
Thiery JP. Nature Reviews Cancer.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Journal of Medicinal Chemistry.
The history entries editors wrote on cancer records: the dated turning points of each disease.
KIT exon 11-mutant GIST
Solid pseudopapillary neoplasm of the pancreas
BRAF V600E-mutant colorectal cancer
BRAF V600-mutant melanoma
BRAF V600E-mutant non-small-cell lung cancer
Melanoma. Davies et al., Nature.
Waldenström macroglobulinaemia
Lung cancer (all types). 1,207 patients, a 19 percent response rate and a median survival of 7.9 months whichever platinum doublet was used.
Localised penile cancer (organ-confined, node-negative)
Dermatofibrosarcoma protuberans
Chromophobe renal cell carcinoma
HR-positive / HER2-negative breast cancer
Papillary renal cell carcinoma
Non-small-cell lung cancer
Diffuse large B-cell lymphoma. Rituximab added to CHOP raises cure rates by ~15 points; the standard for the next twenty years.
Non-Hodgkin lymphoma (all types). Rosenwald profiled 240 biopsies, found germinal-centre, activated and type 3 subgroups and built a 17-gene survival predictor independent of the I...
Parathyroid carcinoma. Carpten and colleagues, Nat Genet.
Gastrointestinal stromal tumour (GIST)
Sarcomas (soft tissue, bone, GIST)
Sarcomas (soft tissue, bone, GIST)
Extragonadal germ cell tumour. Bokemeyer and colleagues pool 635 patients from eleven centres: seminomas do as well as testicular disease, mediastinal non-seminomas do worst, and p...
Intermediate hepatocellular carcinoma (BCLC B)
Soft tissue sarcoma of the extremity (localised and advanced)
T-cell/histiocyte-rich large B-cell lymphoma. A review of 30 cases separated three appearances of the large cells and showed nuclear BCL6 in 26 of 29, placing the tumour cell in th...
Hepatocellular carcinoma
Breast cancer (all types). NSABP B-06 and Milan I both report at twenty years and NSABP B-04 at twenty-five, none of them finding a survival advantage for the larger operation.
Undifferentiated pleomorphic sarcoma (UPS)
Myxofibrosarcoma
Perivascular epithelioid cell tumour (PEComa)
Metastatic cancer (cancer that has spread). Bisphosphonates, then denosumab, cut fractures and other skeletal events from bone metastases.
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Saint-Genis-Pouilly
Bridgewater, New Jersey
Jena
Taipei
Wedel
Boston, MA
Beijing
Kusatsu
The founded year on journal records.
Taylor & Francis (formerly Landes Bioscience)
Cell Press (Elsevier)
SAGE Publishing
BMC (Springer Nature)
American Association for Cancer Research
Springer Nature
SAGE Publishing
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Journal of Clinical Investigation
Journal of Clinical Oncology
The Oncologist
NEJM
Psychosomatic Medicine
Cancer
JCO
Stroke
Seminars in Oncology
Journal of Clinical Oncology
Nature Medicine
New England Journal of Medicine